# Combination Anti-Platelet and Anti-Coagulation Treatment After Lysis of Ischemic Stroke Trial (CATALIST)

> **NCT00061373** · PHASE2 · COMPLETED · sponsor: **National Institute of Neurological Disorders and Stroke (NINDS)** · enrollment: 18 (actual)

## Conditions studied

- Ischemic Stroke

## Interventions

- **DRUG:** Aspirin
- **DRUG:** tinzaparin sodium
- **DRUG:** eptifibatide

## Key facts

- **NCT ID:** NCT00061373
- **Lead sponsor:** National Institute of Neurological Disorders and Stroke (NINDS)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-05
- **Primary completion:** 2009-12
- **Final completion:** 2011-07
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2013-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00061373

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00061373, "Combination Anti-Platelet and Anti-Coagulation Treatment After Lysis of Ischemic Stroke Trial (CATALIST)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00061373. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*